In this phase I/II trial, 143 participants harbouring a RET-mutant MTC (55 previously treated with a multikinase inhibitor) received a dose of 20 to 240 mg twice daily (phase 1) or 160 mg twice daily (phase 2). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.